

06/25/99



A

Patent Application
 ASSISTANT COMMISSIONER FOR PATENTS
 Washington, D.C. 20231

FORM PTO-1082
 Case Docket No. PD-0310
 Date: June 25, 1999
 Express Mail Label No. EL 305 705 455 US

Dear Sir:

Transmitted herewith for filing is the patent application of
 Inventor(s): **WILLIAM P. VAN ANTWERP; ANDREAS PFUETZNER**
 For: **MULTIPLE AGENT DIABETES THERAPY**



Enclosed are:


- ☒ cover sheet, 24 page(s) application, 71 claims, and 1 page abstract
- ☒ An assignment of the invention to MINIMED INC.
- ☒ (executed) Declaration
- ☒ Power of Attorney by Assignee
- ☒ Information Disclosure Statement with 6 references
- ☒ PTO -1449

CALCULATION OF FEES						
ITEM		NO. OF CLAIMS FILED MINUS BASE*	NO. OF CLAIMS OVER BASE	X SM/LG ENTITY FEE	\$ AMOUNT	\$ FEE
A	TOTAL CLAIMS FEE	71- 20* =	51	X \$9 or X \$18	\$918	
B	INDEPENDENT CLAIMS FEE**	6- 3* =	3	X \$39 or X 78	\$234	
C	SUBTOTAL - ADDITIONAL CLAIMS FEE (ADD FINAL COLUMN IN LINES A + B)					\$1,152
D	SMALL ENTITY FEE = \$130 MULTIPLE-DEPENDENT CLAIMS FEE LARGE ENTITY FEE = \$260					\$
E	SMALL ENTITY FEE = \$380 BASIC FEE*LARGE ENTITY FEE = \$760					\$760
F	TOTAL FILING FEE (ADD TOTALS FOR LINES C, D, AND E)					\$1,912
F	ASSIGNMENT RECORDING FEE \$ 40					\$40
	**LIST INDEPENDENT CLAIMS 1, 21, 41, 51, 58, 59					

- ☒ Please charge my Deposit Account No. 50-0621 the amount of \$1,952 **A copy of this letter is enclosed.**
- ☐ A check in the amount of \$ to cover the filing fee is enclosed.
- ☐ A check in the amount of \$ to cover Assignment Recordation fee is enclosed.

- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No.
- ☒ Any additional filing fees required under 37 CFR 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No.
- ☒ Any patent application processing fees under 37 CFR 1.17.
- ☐ The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).
- ☒ Any filing fees under 37 CFR 1.16 for presentation of extra claims.

Respectfully submitted,



Paul H. Kovelman
Reg. No. 35,228

Date: June 25, 1999

MiniMed Inc.
12744 San Fernando Road
Sylmar, CA 91342
Telephone: (818) 362-2358 ext. 3313
Facsimile: (818) 367-1458

Table 1. Continued	
1	100
2	100
3	100
4	100
5	100
6	100
7	100
8	100
9	100
10	100
11	100
12	100
13	100
14	100
15	100
16	100
17	100
18	100
19	100
20	100
21	100
22	100
23	100
24	100
25	100
26	100
27	100
28	100
29	100
30	100
31	100
32	100
33	100
34	100
35	100
36	100
37	100
38	100
39	100
40	100
41	100
42	100
43	100
44	100
45	100
46	100
47	100
48	100
49	100
50	100
51	100
52	100
53	100
54	100
55	100
56	100
57	100
58	100
59	100
60	100
61	100
62	100
63	100
64	100
65	100
66	100
67	100
68	100
69	100
70	100
71	100
72	100
73	100
74	100
75	100
76	100
77	100
78	100
79	100
80	100
81	100
82	100
83	100
84	100
85	100
86	100
87	100
88	100
89	100
90	100
91	100
92	100
93	100
94	100
95	100
96	100
97	100
98	100
99	100
100	100

FOR

DOCKET NO. PD-0310

MICHAEL M. GERARDI, Reg. No. 33,698

12744 San Fernando Road

Sylmar, California 91342

(818) 362-2358 ext. 3313

(818) 367-1458 facsimile

Express Mail No. EL 305 705 455 US

MULTIPLE AGENT DIABETES THERAPY

Field of the Invention

The present invention relates to pharmaceutical compositions useful in the treatment of diabetes, and more particularly to compositions useful in treating both diabetes and one or more side effects thereof. The present invention also relates to methods of treating diabetes using such compositions.

Background of the Invention

Diabetes mellitus is a metabolic disorder characterized by chronically elevated levels of blood glucose, or hyperglycemia, which results from a reduction or absence of activity of the peptide hormone insulin. Insulin, which is produced and secreted by the beta cells of the pancreas, promotes the utilization of glucose and is essential to the maintenance of blood levels of glucose within the normal physiological range.

Included within the scope of the term diabetes mellitus are two states: Type 1, also known as insulin-dependent diabetes mellitus (IDDM), and Type 2, or non-insulin-dependent diabetes mellitus (NIDDM). Type 1 diabetes is characterized by a deficiency or absence of insulin, such that the level of blood glucose cannot be maintained within the normal range, and must be treated by administration of insulin to the patient. Type 2 diabetes is characterized by either or both a state of insulin resistance or impaired insulin sensitivity or reduced insulin secretion, that is, a state in which insulin does not produce the expected decrease in blood glucose concentrations, resulting in hyperglycemia.

Insulin and insulin analogs are commonly administered to diabetic patients, particularly Type 1 patients, in an injectable composition which comprises a pharmaceutically acceptable carrier and typically one or more conventional excipients. It is believed to be desirable to include in such

compositions one or more peptides, in particular peptides that are naturally secreted by the pancreas together with insulin in non- iabetics. Such peptides are herein referred to as "insulin-related peptides".

One problem that is expected to arise in preparing such compositions is that most peptides are not as stable thermally as insulin. A need therefore exists for a thermally stable composition that includes insulin or an insulin analog together with at least one insulin-related peptide, peptide fragment or peptide analog.

Certain therapies for Type 2 diabetes do not require the administration of insulin. Such therapies, however, typically act by stimulating the release of insulin from the pancreatic beta cells. In these therapies, the pancreas can be subjected to undesirable stress. A need therefore also exists for an improved composition that does not cause excessive stress to the pancreas of the patient to whom the composition is administered.

A need also exists for method of preparing such compositions and administering such compositions to a patient.

Summary of the Preferred Embodiments

In accordance with one aspect of the present invention, there is provided a pharmaceutical composition that includes at least two of agents chosen from the group of agents i) - iii). In the inventive composition, agent i) is selected from the group consisting of an insulin, an insulin analog or a physiologically active fragment of the insulin or insulin analog, agent ii) is selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment, or a physiologically active insulin-related peptide analog fragment, and agent iii) is an insulin sensitizer.

According to one more particular embodiment, the inventive composition includes agents i) and ii) above. More particularly, the composition further includes a pharmaceutically acceptable non-ionic surfactant.

According to another more particular embodiment, the inventive composition includes agents i) and iii) above.

According to another more particular embodiment, the inventive composition includes agents ii) and iii) above. This embodiment is beneficially employed in treating Type 2 diabetes.

In accordance with another aspect of the present invention, there is provided a pharmaceutical composition that includes at least one agent selected from the group consisting of an insulin, an insulin analog, a physiologically active insulin fragment and a physiologically active insulin analog fragment, and at least one agent selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulated-related peptide analog fragment. The second agent has a hydrophobic portion that is coated with a pharmaceutically acceptable non-ionic surfactant.

In accordance with a further aspect of the present invention, methods of treating diabetes are provided that include the step of administering to a patient in need of such treatment the foregoing pharmaceutical compositions.

According to more specific embodiments, the compositions are administered to the patient by a medication infusion pump. Preferably, the compositions are continually administered to the patient.

In accordance with still another aspect of the present invention, a method of treating diabetes is provided that includes the step of administering to a patient in need of such treatment at least two pharmaceutical compositions chosen from the group of compositions a)-c). Composition a) includes at least one insulin, insulin analog or fragment thereof as described herein. Composition b) includes at least one insulin-related peptide, peptide analog or fragment thereof. Composition c) includes at least one insulin sensitizer. Each composition also includes a pharmaceutically acceptable carrier.

In more specific embodiments, each composition is administered using a separate delivery device, in particular an external or internal medication infusion pump, and at different rates. Preferably each composition is administered continually.

- 5 In one particular preferred embodiment, compositions a) and b) are administered to the patient. In this embodiment, composition b) preferably further includes at least one pharmaceutically acceptable non-ionic surfactant.

Methods of making the inventive compositions are also provided.

- Other objects, features and advantages of the present invention will
10 become apparent to those skilled in the art from the following detailed description. It is to be understood, however, that the detailed description and specific examples, while indicating preferred embodiments of the present invention, are given by way of illustration and not limitation. Many changes and modifications within the scope of the present invention may be made without
15 departing from the spirit thereof, and the invention includes all such modifications.

Detailed Description of the Preferred Embodiments

- It has been discovered that the administration of two or more distinct
20 types of agent, in multiple agent pharmaceutical compositions as described herein or in separate compositions that are coadministered or sequentially administered, e.g, via medication infusion pumps, is effective in treating both diabetes and one or more diabetes side-effects.

- As used herein, an "insulin analog" is a peptide that has insulin-like
25 physiological activity, i.e., binds an insulin receptor and lowers blood glucose, and that includes one or more amino acids different from the amino acid sequence of a naturally occurring insulin. Likewise, an "insulin-related peptide analog" is a peptide that has the physiological activity of an insulin-related

peptide and an amino acid sequence that differs in at least one position from the amino acid sequence of the insulin-related peptide. A "physiologically active fragment" of an insulin, insulin analog, insulin-related peptide or insulin-related peptide analog is a molecule that includes less than the full amino acid sequence of the respective peptide but that has substantially the same physiological activity as the complete peptide, preferably at least about 70% of the activity of the complete peptide.

Also as used herein, an "insulin sensitizer" is a compound that increases a patient's response to, or decreases the patient's resistance to, insulin.

For present purposes, all references to "insulin", "insulin analog" and "insulin-related peptide" will encompass analogs and physiologically active fragments of such molecules.

A first preferred embodiment of the inventive pharmaceutical composition combines therapeutically effective amounts of an insulin with an insulin-related peptide. More preferably, this embodiment also includes a non-ionic surfactant. Use of non-ionic surfactants according to the invention affords thermally stable compositions. Non-ionic surfactants according to the invention are used to create safe domains which protect the relatively more thermally unstable insulin-related peptides. The protection afforded by the surfactants enables effective co-administration of the insulin and the selected insulin-related peptide.

The inventive compositions according to this embodiment preferably include an insulin selected from the group consisting of human insulin, porcine insulin and bovine insulin. Combinations of two or more different insulins can also be used. The insulin can be a naturally occurring insulin, a semisynthetic insulin, a synthetic insulin or a recombinant insulin.

Insulin analogs that are useful according to the invention include, without limitation, "Lyspro" (commercially available from Eli Lilly Co.), Lys^{B28} insulin, Pro^{B29} insulin and Asp^{B28} insulin. Other insulin analogs that are useful according to the invention are described, e.g., in U.S. Patent No. 5,149,777 and U.S.

Patent No. 5,514,646, which are incorporated herein by reference.

Combinations of two or more insulin analogs can also be used.

Insulin-related peptides that are useful according to the invention include, without limitation: C-peptide, which is useful in protecting microvasculature against glycosylation-related damage, and which in addition delays gastric emptying; GLP-1, which also delays gastric emptying; amylin; IGF-1, which functions to maintain glucostasis; and IGF-1 bound to binding protein 3 (somatokine), which does not produce hyperglycemia and is therefore particularly useful for treating type 2 diabetes.

Non-ionic surfactants useful according to this embodiment of the invention include, without limitation, block copolymers of propylene oxide and ethylene oxide. Exemplary surfactants include those commercially available from the BASF Corporation under the name Pluronic®, such as Pluronic F20, Pluronic F28, Pluronic F68, Tween 20, Tween 40 and Brij, and those commercially available under the name Genapol®, such as Genapol 1800. The non-ionic surfactant preferably is pharmaceutically acceptable. Combinations of two or more non-ionic surfactants can also be used.

When a non-ionic surfactant is used, preferably, the amount of the non-ionic surfactant in the composition is less than that which results in a two-phase composition. That is, the concentration of the surfactant in the composition is below the critical micellar concentration of the composition. The critical micellar concentration will vary depending on the particular agents used to form the composition, but is readily determined by those skilled in the art through routine experimentation.

Thus, in the foregoing preferred embodiment, the inventive composition preferably includes about 1.5 to about 40 mg/ml of the insulin or combination of insulins, more particularly about 3.5 to 3.5 mg/ml, about 1.5 to about 40 mg/ml, more particularly about 4 to 10 mg/ml, of the selected insulin-related peptide(s), and an amount of the selected surfactant(s) such that the concentration of the

selected surfactant in the composition is less than the critical micellar concentration.

At lower surfactant concentrations, a "micro" two-phase composition is formed in which the surfactant coats the hydrophobic portions of the insulin-related peptide. This surfactant coating also increases the thermal stability of the peptide. Thus, in another preferred embodiment of the invention, a pharmaceutical composition is provided which includes i) an insulin and ii) an insulin-related peptide that includes a hydrophobic portion that is coated with a non-ionic surfactant. The amount of the non-ionic surfactant present in the composition preferably is sufficient to completely coat all hydrophobic portions of the insulin-related peptide.

A more specific preferred embodiment of the foregoing pharmaceutical composition further includes a therapeutically effective amount of at least one insulin sensitizer. Preferred insulin sensitizers include compounds of the glitazone family. These include, for example, the compounds described in U.S. Patent No. 5,753,681, incorporated herein by reference, such as troglitazone, pioglitazone, englitazone and related compounds. When insulin sensitizers are included in the foregoing pharmaceutical composition, they preferably are present in amounts ranging from 0.2 to 1.4 mg/ml, more preferably about 0.5 to 0.8 mg/ml.

According to a second preferred embodiment, the inventive pharmaceutical composition includes an insulin and an insulin sensitizer (i.e., agents i) and iii)). The amounts of the insulin and insulin sensitizer are typically the same as those set forth in connection with the preceding embodiment, i.e., about 1.5 to 40 mg/ml, more particularly about 3.5 to 14 mg/ml of an insulin or combination of insulins, and about 0.2 to 1.4 mg/ml, more particularly about 0.5 to 0.8 mg/ml of one or more insulin sensitizers.

According to a third preferred embodiment, the inventive pharmaceutical composition includes an insulin-related peptide and an insulin sensitizer (i.e.,

agents ii) and iii)). The amounts of the insulin and insulin sensitizer are typically the same as those set forth in connection with the preceding embodiment, i.e., about 1.5 to 40 mg/ml, more particularly about 4 to 10 mg/ml of an insulin-related peptide or combination of insulin-related peptides, and about 0.2 to 1.4 mg/ml, more particularly about 0.5 to 0.8 mg/ml of one or more insulin sensitizers.

The inventive compositions are preferably formulated to include one or more pharmaceutically acceptable carriers and optionally additional conventional excipients such as diluents, buffers, preservatives, pH adjusters, etc. The compositions can be prepared by a variety of known techniques, for example those described in *Remington's Pharmaceutical Sciences*, 17th Edition, Mack Publishing Company, Easton, PA, USA (1985), which is incorporated herein by reference.

The inventive compositions are particularly useful in treating patients suffering from diabetes together with one or more diabetes side effects. The compositions can be administered to patients in need of such treatment by any desired route, such as subcutaneous, pulmonary, etc. In particular, the inventive compositions can be administered by means of medication infusion pumps, which can be reusable or non-reusable (i.e., disposable), and implantable or externally mountable. Medication infusion pumps that are usefully employed for this purpose include, without limitation, the pumps disclosed in copending, commonly assigned U.S. Patent Applications Serial No. 09/253,382 and 09/253,383, filed February 19, 1999; in U.S. Patent No. 5,637,095, to Nason et al., entitled "Medication Infusion Pump with Flexible Drive Plunger"; in U.S. Patent No. 5,569,186, to Lord et al., entitled "Closed Loop Infusion Pump System with Removable Glucose Sensor"; and in U.S. Patent No. 5,527,307, to Srisathapat et al., entitled "Implantable Medication Pump with Implantable Pressure Reservoir". The compositions can be administered continually from such devices, or can be administered intermittently.

According to one method of the invention, a pharmaceutical composition that includes two or more of agents i) – iii) as described is administered to a patient in need of such treatment.

- 5 According to an alternative method of treatment, two (or more) separate compositions are administered to the patient, either simultaneously or sequentially, and more specifically using separate delivery devices and delivery rates for each composition.

Each such composition includes one (or more) of agents i) – iii) as described herein.

- 10 The invention is further illustrated by the following non-limiting examples.

Example 1

Insulin	4 mg/ml
C-Peptide	2.5 mg/ml
Genapol 1800	17 ug/ml
Glycerin	16 mg/ml
Zinc	0.36 mg/ml
Phosphate buffer	1.96 mg/ml

- 15 PH 7.4

The composition is suitable for administration using an externally mounted medication infusion pump.

Example 2

Insulin	15.8 mg/ml
GLP-1	4.1 mg/ml
Pluronic F20	0.11 mg/ml
Glycerin	16 mg/ml
Zinc	0.36 mg/ml
Phosphate buffer	1.96 mg/ml

PH 7.0-7.8

- 5 The composition is suitable for administration using an implantable medication infusion pump.

Example 3

Insulin	4 mg/ml
IGF-1	1.1 mg/ml
Tween 20	0.1 mg/ml
Glycerin	16 mg/ml
Zinc	0.36 mg/ml
Phosphate buffer	1.96 mg/ml

Example 4

Insulin	4 mg/ml
IGF-1 bound to binding protein 3	2.2 mg/ml
Tween 40	0.1 mg/ml
Glycerin	16 mg/ml
Zinc	0.36 mg/ml
Phosphate buffer	1.96 mg/ml

Example 5

5

Lys ^{B28} Pro ^{B29} insulin	4 mg/ml
C-peptide	2.5 mg/ml
Genapol	0.01 mg/ml
Glycerin	16 mg/ml
Zinc	0.36 mg/ml
Phosphate buffer	1.96 mg/ml

Example 6

Insulin	4 mg/ml
Troglitazone	1.1 mg/ml
Phosphate buffer	1.96 mg/ml

Example 7

5

Insulin	15.8 mg/ml
C-peptide	2.5 mg/ml
Troglitazone	1.0 mg/ml
Genapol	0.01 mg/ml
Glycerin	16 mg/ml
Zinc	0.36 mg/ml
Phosphate buffer	1.96 mg/ml

In alternative embodiment, the insulin and/or insulin analog are replaced by an insulin mimetic material that functions to activate the human insulin receptor. Examples of suitable insulin mimetic materials are shown and described in U.S. Provisional Patent Application Serial No. 60/135,278 filed on May 21, 1999 and entitled "Device and Method for Infusion of Small Molecule Insulin Mimetic Materials, which is specifically incorporated by reference herein and forms a part of this disclosure.

While the description above refers to particular embodiments of the present invention, it will be understood that many modifications may be made without departing from the spirit thereof. The accompanying claims are intended to cover such modifications as would fall within the true scope and spirit of the present invention.

The presently disclosed embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims, rather than the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

5

SECRET

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising at least two of agents i) – iii),
wherein
5 agent i) is selected from the group consisting of an insulin, an insulin
analog, a physiologically active fragment of said insulin and a physiologically
active fragment of said insulin analog,
agent ii) is selected from the group consisting of an insulin-related
peptide, an insulin-related peptide analog, a physiologically active insulin-related
10 peptide fragment and a physiologically active insulin-related peptide analog
fragment, and
agent iii) is an insulin sensitizer.
- 15 2. The composition of claim 1 wherein said agent i) is an insulin.
3. The composition of claim 2 wherein said insulin is selected from the
group consisting of human insulin, porcine insulin and bovine insulin.
- 20 4. The composition of claim 1 wherein said agent i) is an insulin analog.
5. The composition of claim 4 wherein said insulin analog is selected from
the group consisting of Lys^{B28} insulin, Pro^{B29} insulin and Asp^{B28} insulin.
- 25 6. The composition of claim 1 wherein said agent ii) is an insulin-related
peptide.
7. The composition of claim 6 wherein said peptide is selected from the group
consisting of C-peptide, GLP-1, amylin, IGF-1 and IGF-1 bound to binding
protein 3.

8. The composition of claim 1 wherein said agent iii) is an insulin sensitizer of the glitazone family.
- 5 9. The composition of claim 1 which is stabilized for administration by a medication infusion pump.
10. The composition of claim 1 comprising agent i) and agent ii).
- 10 11. The composition of claim 1 comprising about 1.5 to about 40 mg/ml of agent i) and about 1.5 to about 40 mg/ml of agent ii).
12. The composition of claim 10 further comprising a pharmaceutically acceptable non-ionic surfactant.
- 15 13. The composition of claim 12 wherein said non-ionic surfactant is a block copolymer of propylene oxide and ethylene oxide.
14. The composition of claim 13 comprising about 1.5 to about 40 mg/ml of agent i), about 1.5 to about 40 mg/ml of agent ii) and an amount of said non-ionic surfactant affording a concentration less than the critical micellar concentration of said composition.
- 20 15. The composition of claim 9 further comprising agent iii).
- 25 16. The composition of claim 1 comprising agent i) and agent iii).
17. The composition of claim 16 comprising about 0.5 to about 40 mg/ml of agent i) and about 0.05 to about 12 mg/ml of agent iii).

18. The composition of claim 1 comprising agent ii) and agent iii).
19. The composition of claim 18 comprising comprising about 0.05 to about
5 12.5 mg/ml of agent ii) and about 0.05 to about 12.5 mg/ml of agent iii).
20. The composition of claim 1 comprising two or more compounds of agents
i), ii) or iii).
- 10 21. A pharmaceutical composition comprising
- i) at least one agent selected from the group consisting of an insulin,
an insulin analog, a physiologically active insulin fragment and a physiologically
active insulin analog fragment and
- ii) at least one agent selected from the group consisting of an insulin-
15 related peptide, an insulin-related peptide analog, a physiologically active insulin-
related peptide fragment and a physiologically active insulin-related peptide
analog fragment,
- wherein said agent ii) comprises a hydrophobic portion that is coated with
a pharmaceutically acceptable non-ionic surfactant.
- 20 22. The pharmaceutical composition of claim 21 wherein said non-ionic
surfactant is a block copolymer of propylene oxide and ethylene oxide.
23. The pharmaceutical composition of claim 21 further comprising a
25 pharmaceutically acceptable carrier.
24. The pharmaceutical composition of claim 21 further comprising iii) an
insulin sensitizer.

25. The composition of claim 21 which is stabilized for administration by a medication infusion pump.

26. A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 1.

27. The method of claim 26 wherein said composition is administered to said patient by a medication infusion pump.

28. The method of claim 27 wherein said medication infusion pump is reusable.

29. The method of claim 27 wherein said medication infusion pump is non-reusable.

30. The method of claim 27 wherein said medication infusion pump is implantable.

31. The method of claim 27 wherein said medication infusion pump is externally mountable.

32. The method of claim 26 wherein said composition is administered continually.

33. A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 10.

34. A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 12.

35. A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 15.

36. A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 16.

37. A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 18.

38. The method of claim 37 wherein said diabetes is type 2 diabetes.

39. A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 20.

40. A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 21.

41. A method of treating diabetes comprising the step of administering to a patient in need of such treatment at least two pharmaceutical compositions a)-c), wherein

composition a) comprises

- i) at least one agent selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog, and

- ii) a pharmaceutically acceptable carrier,

composition b) comprises

- i) at least one agent selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a

physiologically active insulin-related peptide fragment and a
physiologically active insulin-related peptide analog
fragment, and

ii) a pharmaceutically acceptable carrier, and

5 composition c) comprises

i) an insulin sensitizer, and

ii) a pharmaceutically acceptable carrier.

10 42. The method of claim 41 wherein each of said compositions is
administered to said patient using a separate delivery device.

43. The method of claim 42 wherein each said delivery device is a medication
infusion pump.

15 44. The method of claim 41 wherein each of said compositions is
administered at a different rate.

45. The method of claim 41 wherein each of said compositions is
administered continually.

20

46. The method of claim 41 wherein compositions a) and b) are administered
to said patient.

25 47. The method of claim 46 wherein said composition b) further comprises at
least one pharmaceutically acceptable non-ionic surfactant.

48. The method of claim 41 wherein compositions a) and c) are administered
to said patient

49. The method of claim 41 wherein compositions b) and c) are administered to said patient

50. The method of claim 41 wherein compositions a), b) and c) are administered to said patient.

51. A method of making a pharmaceutical composition useful in treating diabetes, said method comprising the step of combining at least two of agents i) – iii), wherein

10 agent i) is selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog,

agent ii) is selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and

agent iii) is an insulin sensitizer.

52. The method of claim 51 wherein said agents are combined with a pharmaceutically acceptable carrier.

53. The method of claim 51 wherein agents i) and ii) are combined.

54. The method of claim 52 wherein agents i) and ii) are combined with a pharmaceutically acceptable non-ionic surfactant.

55. The method of claim 51 wherein agents i) and iii) are combined.

56. The method of claim 51 wherein agents ii) and iii) are combined.

57. The method of claim 51 wherein agents i), ii) and iii) are combined.

58. A method of treating diabetes and at least one side effect thereof which
5 comprises the step of administering to a patient in need of such treatment a
pharmaceutical composition comprising

a) at least one agent selected from the group consisting of an insulin,
an insulin analog, a physiologically active insulin fragment and a physiologically
active insulin analog fragment,

10 b) at least one agent selected from the group consisting of an insulin-
related peptide, an insulin-related peptide analog, a physiologically active insulin-
related peptide fragment and a physiologically active insulin-related peptide
analog fragment, wherein said agent is effective in treating said side effect, and

c) a pharmaceutically acceptable non-ionic surfactant.

59. A pharmaceutical composition comprising at least two of agents i) – iii),
wherein

agent i) is selected from the group consisting of an insulin mimetic
material,

20 agent ii) is selected from the group consisting of an insulin-related
peptide, an insulin-related peptide analog, a physiologically active insulin-related
peptide fragment and a physiologically active insulin-related peptide analog
fragment, and

agent iii) is an insulin sensitizer.

60. The composition of claim 59 wherein said agent i) is a small molecule
insulin.

61. The composition of claim 60 wherein the small molecule insulin mimetic material is L-783,281.

5 62. The composition of claim 59 wherein said agent ii) is an insulin-related peptide.

63. The composition of claim 62 wherein said peptide is selected from the group consisting of C-peptide, GLP-1, amylin, IGF-1 and IGF-1 bound to binding protein 3.

10

64. The composition of claim 59 wherein said agent iii) is an insulin sensitizer of the glitazone family.

15 65. The composition of claim 59 which is stabilized for administration by a medication infusion pump.

66. The composition of claim 59 comprising agent i) and agent ii).

20 67. The composition of claim 66 further comprising a pharmaceutically acceptable non-ionic surfactant.

68. The composition of claim 67 wherein said non-ionic surfactant is a block copolymer of propylene oxide and ethylene oxide.

25 69. The composition of claim 65 further comprising agent iii).

70. The composition of claim 59 comprising agent i) and agent iii).

Express Mail No. EL 305 705 455 US

DECLARATION

X ORIGINAL
CONTINUATION
DIVISIONAL

As a below named inventor, I declare that the information given herein is true, that I believe that I am the original, first and sole inventor if only one name is listed at 1 below, or a joint inventor if plural inventors are named below at 1-2, of the invention entitled:

MUTIPLE AGENT DIABETES THERAPY

Which is described and claimed in:

X the attached specification or
the specification in application Serial No. _____ filed _____
as amended on _____

and for which a patent is sought, and that my residence, post office address and citizenship are as stated below next to my name.

I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations §1.56(a).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATION(S)

COUNTRY	APPLICATION NUMBER	DATE OF FILING Month Day Year	PRIORITY CLAIMED UNDER 35 U.S.C. 119
			YES _ NO _ YES _ NO _

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

(Application Serial No.) (Filing Date) (Status)

Send correspondence to:
MiniMed, Inc.
12744 San Fernando Road
Sylmar, CA 91342

DIRECT TELEPHONE CALLS TO:
Paul H. Kovelman
(818) 362-2358 ext. 3313

1	LAST NAME VAN ANTWERP	FIRST NAME WILLIAM	MIDDLE NAME P.	Residence: CITY VALENCIA	STATE or COUNTRY CALIFORNIA
	Post Office Address 24101 W. DEL MONTE, #418, VALENCIA, CA 91355				CITIZENSHIP US
2	LAST NAME PFUETZNER	FIRST NAME ANDREAS	MIDDLE NAME H.R.	Residence: CITY	STATE or COUNTRY GERMANY
	Post Office Address HAYDNSTR.14, D-55130 MAINT, GERMANY				CITIZENSHIP GERMANY

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 1 <i>W.P. Van Antwerp</i>	SIGNATURE OF INVENTOR 2 <i>Paul H. Kovelman</i>
DATE 25-June-1999	DATE 6/25/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Art Unit:	Unknown
William P. Van Antwerp et al.)		
Serial No.: unknown)	Examiner:	Unknown
Filed: June 25, 1999)		
For: MULTIPLE AGENT DIABETES)		
<u>THERAPY</u>)		

POWER OF ATTORNEY BY ASSIGNEE
AND EXCLUSION OF INVENTOR UNDER RULE 3.71

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The undersigned **Eric S. Kentor** is a representative authorized to sign on behalf of the assignee of the entire interest in the above-identified subject application, **MiniMed Inc.** and hereby appoints:

Paul H. Kovelman, Reg. No. 35,228
Michael M. Gerardi, Reg. No. 33,698;

and all of the firm of Konrad Raynes & Victor, LLP:

William K. Konrad, Reg. No. 28,868
Alan S. Raynes, Reg. No. 39,809
David Victor, Reg. No. 39,867

to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventor and his attorney in accordance with the provisions of Rule 32 of the Patent Office Rules of Practice.

MiniMed Inc., per 37 C.F.R. §3.73(b), certifies that the evidentiary documents with respect to its ownership have been reviewed and that to the best of the undersign's knowledge and belief, title is in the assignee seeking this action.

MiniMed Inc., declares that 100% ownership is established by an assignment to be in the Regular Utility Patent Application, and that the Inventors are under an obligation to assign the application to **MiniMed Inc.**


Please direct all telephone calls to Paul Kovelman at (818) 362-2358 ext. 3313 and all correspondence relative to said application to the following address:

Paul H. Kovelman
MiniMed Inc.
12744 San Fernando Road
Sylmar, CA 91342

ASSIGNEE: **MiniMed Inc.**

Date: June 25, 1999

Signature: _____



Eric S. Kentor

Title:

Sr. Vice President & Gen. Counsel

Address:

12744 San Fernando Road
Sylmar, CA 91342